Influenza Vaccination Companies
Influenza vaccines play a critical role in preventing and controlling seasonal flu outbreaks. Several pharmaceutical companies are actively involved in the research, development, and production of influenza vaccines.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Influenza Vaccines Companies Update
-
October 2023: Mylab and Serum Institute of India (SII), both based in the city, have introduced Nasovac S4, the first needle-free nasal influenza vaccine in India. Vaccination will be accessible throughout India via a network of clinics and healthcare providers. In accordance with WHO guidelines, Nasovac S4 is a live quadrivalent influenza vaccine comprising four genotypes of the influenza vaccine virus. The vaccine contains two influenza Type B virus strains and two influenza Type A virus strains (A/H1N1 and A/H3N2, according to a statement issued by Mylab Discovery Solutions). Nasovac S4 is recommended for patients older than 2 years old as it effectively immunizes against influenza viruses caused by the specified strains. The action of this nasal spray influenza vaccine is initiated in the nasal passages, where it induces the production of antibodies against influenza infection by the immune system. Nasovac S4 is prescribed for animals older than two years with a single intranasal dosage.
-
November 2023: Integral Molecular, a market leader in vaccine evaluation reagents, introduces TiterSafeâ„¢ influenza virus-like particles in November 2023. These particles serve as a substitute for commercially available viruses and are utilized in critical experiments aimed at testing influenza vaccines. TiterSafe is a convenient and risk-free alternative to live virus that is suitable for high-throughput assays, reduces biosafety risks for laboratory personnel, and is immediately usable. TiterSafe particles emulate the structural characteristics of living viruses by incorporating a protein nucleus and surface influenza proteins hemagglutinin (HA) and neuraminidase (NA). They are devoid of DNA or RNA components, which are critical for virus replication.
List of Influenza Vaccines Key companies in the market
- GlaxoSmithKline PLC (UK)
- Abbott Laboratories (US)
- Seqirus (UK)
- Mylan NV (US)
- AstraZeneca (UK)
- Hualan Biological Engineering Inc. (China)
Influenza Vaccination Market Highlights:
Influenza Vaccination Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
